TORONTO--(BUSINESS WIRE)--Alternate Health Corp. (CSE:AHG) (OTC:AHGIF), a diverse healthcare company revolutionizing patient care and research in the emerging medical cannabis industry, announced an agreement to acquire Neubauer Hyperbaric Neurological Center (NHNC) in Lauderdale-By-The-Sea, Florida, a pioneer and national leader in neurological disorder research and treatment.
Through this acquisition, Alternate Health will be positioned to be a major player in the Florida healthcare market, which is the third most populous state and holds the largest proportion of elderly residents in America. Alternate Health plans to leverage the decades of research, therapeutics, and expertise of the Neubauer Center to expand novel care delivery models and to perform clinical trials.
“Following Florida’s vote last year to legalize medical cannabis, there are countless new opportunities for cannabinoid research and treatment across the state, including the hemp-derived Cannabidiol (CBD) compounds that we are focused on,” said Dr. Jamison Feramisco, CEO, Alternate Health Corp. “The Neubauer Center acquisition strengthens our goal to put patients in charge of their healthcare options, while opening up new revenue streams in untapped markets.”
Founded in 1972 by world-renowned physician Dr. Richard A. Neubauer, the Neubauer Hyperbaric Neurological Center was South Florida’s first Hyperbaric Oxygen Treatment (HBOT) clinic and research facility. For 45 years, the Center has obtained a global reputation as the leader in HBOT research for the treatment of neurological disorders and other illnesses. The late Dr. Neubauer’s family continues to operate the clinic.
Alternate Health and the Neubauer Center are currently collaborating on clinical studies researching the use of Cannabidiol compounds in treating patients suffering from chronic fatigue and persistent pain following the Zika virus infection. Concurrent with the acquisition, Alternate Health plans on both continuing the study of CBD and HBOT treatments in patients suffering from chronic post-flavivirus signs and symptoms and also in other fields of neurologic and mental health research.
About the Neubauer Hyperbaric Neurological Center
Having treated patients since 1972, Neubauer Hyperbaric Neurologic Center is a pioneer in the use of HBOT for neurological conditions in the Greater Miami Area. The results of founder Dr. Neubauer’s scientific studies (through the Center) have been published in a variety of respected medical journals, including Lancet and the Journal of the American Medical Association.
Alternate Health Corp. is a diversified healthcare company that uses its expertise in technology to revolutionize patient care and service delivery in both traditional and complementary medical fields. With investments in research, education and cutting edge technology, Alternate Health is a leader in software applications and processing systems for the medical industry using proprietary technology platforms. Through its subsidiaries, Alternate Health offers services ranging from medical practice and controlled substance management software to blood analysis and toxicology labs, to clinical research and continuing education programs. Alternate Health’s goal is to continue to lead the medical industry with data-driven results in patient care and product development.
Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as “forward-looking statements”. Forward-looking statements may be identified by words including “anticipates”, “believes”, “intends”, “estimates”, “expects” and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company’s future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements.
